BIOMAT Database Logo BIOMAT Database Logo

Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery. 1988

M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Department of Orthopaedics, Aalborg Hospital, Denmark.

In a prospective, double-blind controlled study we have compared the prophylactic efficacy against deep vein thrombosis of low-dose heparin + dihydroergotamine (A), low molecular weight heparin + dihydroergotamine (B) and placebo (C). A total of three hundred and fifty-six patients undergoing total hip replacement were randomized into three groups and 316 patients were analysed. All thrombi were verified by ascending phlebography. One-third of the patients developed deep vein thrombosis in group A and B, differing significantly from group C. The operative blood loss in group B was higher than that in groups A and C. However, the number of patients transfused and their transfusion requirements did not differ. Severe bleeding occurred in one patient in each group. No deaths were registered during the study. Our study indicates that prophylactic treatment against postoperative deep vein thrombosis with low molecular weight heparin + dihydroergotamine once daily is as effective and safe as conventional low-dose heparin + dihydroergotamine twice daily in patients undergoing total hip replacement. The once-daily regimen has the advantage of better patient acceptance and less nursing time.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004087 Dihydroergotamine A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. Agit,Angionorm,Clavigrenin,D-Tamin Retard L.U.T.,D.H.E. 45,DET MS,DHE-45,DHE-Puren,DHE-Ratiopharm,Dihydergot,Dihydroergotamin AL,Dihydroergotamine Mesylate,Dihydroergotamine Methanesulfonate,Dihydroergotamine-Sandoz,Dihytamin,Erganton,Ergomimet,Ergont,Ergotam Von Ct,Ikaran,Migranal,Orstanorm,Seglor,Tamik,Verladyn,D Tamin Retard L.U.T.,DHE 45,DHE Puren,DHE Ratiopharm,DHE45,Dihydroergotamine Sandoz,Mesylate, Dihydroergotamine,Methanesulfonate, Dihydroergotamine,Von Ct, Ergotam
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females

Related Publications

M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Venous thrombosis prophylaxis with low-molecular-weight heparin in hip and knee arthroplasty.
January 2002, Instructional course lectures,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
[Prophylaxis of venous thrombosis and low-molecular-weight heparin].
September 1991, Medicina clinica,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis.
September 1986, The British journal of surgery,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough?
July 2010, World journal of surgery,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
[Prophylaxis for deep vein thrombosis with low molecular weight heparin following hip and knee surgery].
January 2001, Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Thrombosis prophylaxis with low molecular weight heparin in total hip replacement.
November 1988, The British journal of surgery,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.
September 1992, The British journal of surgery,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
[Combination of low molecular weight heparin and dihydroergotamine for prevention of thrombosis].
April 1995, Deutsche medizinische Wochenschrift (1946),
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Low-molecular-weight heparin and venous thrombosis.
February 1991, Annals of internal medicine,
M R Lassen, and L C Borris, and H M Christiansen, and F Møller-Larsen, and V E Knudsen, and P Boris, and A M Nehen, and A de Carvalho, and A G Jurik, and B W Nielsen
Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine.
July 1987, Arzneimittel-Forschung,
Copied contents to your clipboard!